Protective effect of empagliflozin against palmitate-induced lipotoxicity through AMPK in H9c2 cells
Min-Woo Song, Wenhao Cui, Chang-Gun Lee, Rihua Cui, Young Ho Son, Young Ha Kim, Yujin Kim, Hae Jin Kim, Sung-E. Choi, Yup Kang, Tae Ho Kim, Ja Young Jeon, Kwan-Woo Lee · 2023
Read Protective effect of empagliflozin against palmitate-induced lipotoxicity through AMPK in H9c2 cells by Min-Woo Song, Wenhao Cui, Chang-Gun Lee, Rihua Cui, Young Ho Son, Young Ha Kim, Yujin Kim, Hae Jin Kim, Sung-E. Choi, Yup Kang, Tae Ho Kim, Ja Young Jeon, Kwan-Woo Lee (2023) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-10728651.txt.
Description
Min-Woo Song and co-authors test whether a diabetes drug can shield heart cells from fat overload, in a study from 2023. The drug, empagliflozin, blocks sugar uptake in the kidney and has shown heart gains. Whether it guards heart cells directly was unknown. The team stressed rat heart cells with a fatty acid that mimics overload.
The drug cut the harm across many fronts. Insulin response recovered, stress in the cell's folding rooms eased, and fewer cells died. Inflammation signals fell as well. The drug raised a key energy sensor and a gene that burns fat for fuel. With fat burning up, stress signals fell further. The authors say the path runs through that energy sensor. The find adds a direct cell-level case for the drug's heart benefits.
Catalog record
| CREATOR | Min-Woo Song, Wenhao Cui, Chang-Gun Lee, Rihua Cui, Young Ho Son, Young Ha Kim, Yujin Kim, Hae Jin Kim, Sung-E. Choi, Yup Kang, Tae Ho Kim, Ja Young Jeon, Kwan-Woo Lee |
|---|---|
| YEAR | 2023 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 30 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |